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Authors' objectives
To determine the cost-effectiveness of influenza vaccination in people aged 65-74 years in the absence of co-morbidity.
Authors' conclusions
No difference was seen between groups for the primary outcome measure (GP attendance with influenza-like illness (ILI) or pneumonia), although the trial was underpowered to demonstrate a true difference. Vaccination had no significant effect on any of the QoL measures used, although vaccinated individuals were less likely to self-report ILI.
Our analysis did not suggest that influenza vaccination in healthy people aged 65-74 years would lead to lower NHS costs. A significant protective effect of influenza vaccine was found for the reduction of self-reported ILI, but the study was not sufficiently powered to examine the effect of influenza vaccination on mortality, GP consultations for respiratory illness or hospital admissions for pneumonia-and influenza-associated respiratory illness.
